Amy Horton Sells 12,430 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Trading Up 0.2 %

AORT stock traded up $0.06 during midday trading on Wednesday, hitting $26.33. The company had a trading volume of 173,589 shares, compared to its average volume of 226,079. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -109.46 and a beta of 1.74. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $29.24. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The stock’s 50 day moving average price is $25.79 and its 200 day moving average price is $24.01.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. As a group, equities research analysts expect that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of Artivion

Several large investors have recently modified their holdings of the business. Perceptive Advisors LLC increased its position in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares during the period. The Manufacturers Life Insurance Company raised its stake in Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock worth $392,000 after buying an additional 481 shares in the last quarter. Marshall Wace LLP purchased a new stake in Artivion in the second quarter worth about $366,000. Public Sector Pension Investment Board boosted its position in Artivion by 7.8% during the 2nd quarter. Public Sector Pension Investment Board now owns 87,273 shares of the company’s stock valued at $2,239,000 after acquiring an additional 6,344 shares in the last quarter. Finally, RW Investment Management LLC purchased a new position in shares of Artivion during the 2nd quarter worth approximately $219,000. 86.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

AORT has been the subject of several research analyst reports. Lake Street Capital lifted their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Oppenheimer increased their price target on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Artivion in a report on Friday, September 27th.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.